BioSpace News Archive

Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, today reported financial results for the fiscal second quarter and first half ended December 31, 2022.

BeiGene, a global biotechnology company, announced the appointment of Julius Pryor III as its first Global Head of Diversity and Health Equity, effective immediately.

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) today announced that it has entered into a platform research evaluation collaboration and option agreement with Regeneron Pharmaceuticals, Inc.

AngioDynamics, Inc. (NASDAQ: ANGO) today announced financial results for the third quarter of fiscal year 2023, which ended February 28, 2023.

Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today announced that John Celebi, president and chief executive officer, will participate in a panel titled ‘Novel Approaches in Immunotherapy’ at Cantor Fitzgerald’s Future of Oncology Virtual Symposium on Monday, April 3rd at 10.00 a.m. ET.

CorMedix Inc. announced financial results for the fourth quarter and full year ended December 31, 2022 and provided an update on recent business developments.

Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the year ended December 31, 2022.

Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women’s needs by developing a suite of products and product candidates that include minimally invasive, in-office technologies for reproductive health, today announced financial results for the year ended December 31, 2022 and provided a corporate update.

aTyr Pharma, Inc. announced the publication of a review article, titled, “Efzofitimod: a novel anti-inflammatory agent for sarcoidosis,” in the peer-reviewed journal Sarcoidosis, Vasculitis and Diffuse Lung Diseases.

Apollomics Inc., a clinical-stage biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, announced the completion of its business combination with Maxpro Capital Acquisition Corp.